RxDoctor Payments Data

Ahmad Alratroot, MD

Pulmonary Disease · Sylvania, OHNPI 1144673260

Payments from drug & device makers

$1,636in general payments, 2019–2025

Across 76 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$342
  • Baxter Healthcare$192
  • Regeneron Healthcare Solutions, Inc.$171
  • United Therapeutics Corporation$106
  • GSK$95
  • Sanofi-aventis U.S. LLC$79
  • plus $651 from 20 others

What the payments were for

  • Food & beverage$1,46790%
  • Education$16910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,636 in reported general payments places this provider in the 45th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$42,654
Medicare patients
202
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter149$116,236
Breo ElliptaFluticasone/Vilanterol52$25,620
Incruse ElliptaUmeclidinium Bromide50$24,988
Spiriva RespimatTiotropium Bromide36$22,660
Advair HfaFluticasone Propion/Salmeterol50$21,140
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,511
Spiriva HandihalerTiotropium Bromide15$10,391
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate37$8,335
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,594
DuleraMometasone/Formoterol18$4,918
Albuterol Sulfate HfaAlbuterol Sulfate127$3,920
BreynaBudesonide/Formoterol Fumarate28$3,230
SymbicortBudesonide/Formoterol Fumarate12$2,778
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,081
Montelukast Sodium80$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$95$173,439264 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$53$34,17152 claims
MerckDulera$41$4,91818 claims
AstraZenecaSymbicort$342$2,77812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →